To the Editor: Dr Coovadia and colleagues1 reported on an innovative randomized controlled trial of 2 antiretroviral treatment (ART) strategies in nevirapine-exposed infants. The trial provided important new information regarding the option of switching to nevirapine-based ART after 3 months of viral suppression with lopinavir/ritonavir–based ART or continuing with the latter. In this study, the superior treatment strategy depended on whether virologic failure was defined by one plasma viral load greater than 50 copies/mL (the primary end point) or a confirmed viral load greater than 1000 copies/mL.
Thor A. Wagner, Lisa M. Frenkel. Antiretroviral Treatment for HIV-Infected Infants Exposed to Nevirapine. JAMA. 2010;304(23):2589–2590. doi:10.1001/jama.2010.1818